BeiGene

BeiGene is a global biotechnology firm that focuses on creating cancer-treatment medications. The company, founded in 2010 by Xiaodong Wang and CEO John V. Oyler, has offices in Asia, North America, Australia, and Europe. BeiGene has created various medications, including the checkpoint inhibitor tislelizumab and the zanubrutinib.

From the start, their R&D team has been focused on developing a pipeline of potentially first-in-class and best-in-class compounds. They are collaborating with one of the world's largest oncology research teams and a worldwide clinical development organization that handles hundreds of clinical trials to achieve this goal. Their clinical trial outcomes, regulatory approvals, and collaborations attest to the strength and quality of their work.

Every day, cancer patients throughout the world face unmet medical needs: some struggle to find treatments that are sufficiently effective against their disease; others discover a promising treatment but are unable to pay for it. They are developing a creative, high-value product candidate portfolio centered on hematology and solid tumors, intending to identify more first-in-class or best-in-class revolutionary therapies. It's all about developing effective treatments that are accessible and cheap to a greater number of patients around the world.

Their approach to cancer biology combines cutting-edge research models and drug discovery methodologies with the scope of a worldwide enterprise. BeiGene is primarily interested in immuno-oncology, which is a key component of cancer treatment. There is enormous potential for cancer immunotherapies to be combined in synergistic ways, as well as for cancer immunotherapies to be combined with other medicines.

BeiGene has developed a wide range of unique in vitro, ex vivo, and in vivo cancer models to assist us in better-selecting targets and screening and evaluating compounds that may have substantial promise, either alone or in combination. To design new cancer models, it is critical that our discovery engine considers tumor-immune system interactions and primary tumor biopsies. Their cancer models, which incorporate aspects of the human immune system, allow them to test possible drug candidates in situations that simulate cancer throughout therapy. This is especially important when drug research is based on assessing different combinations and regimens that target specific mutations while immobilizing cancer cells' defenses.

Founded: 2010 in Beijing, China

Founder: Xiaodong Wang, John V. Oyler

Headquarters: Beijing, China

Website: https://www.beigene.com/